Mitomycin 2mg Injection Franchise in Ahmedabad

Anticancer Chemotherapy Injection Supplier in Mumbai

Mitomule 2 Injection Distributor in Delhi

Oncology Chemotherapy Injection Franchise Opportunity in Bangalore

Cancer Treatment Injection Stockist in Hyderabad
Mitomycin 2mg Export & Manufacturing in Chandigarh

Home/Products /mitomycin-2mg-injection

Mitomule 2 Injection

Composition : Mitomycin (2mg) Injection

Dosage Form : Injection

Packaging Type : Vial

Packaging : 2mg

Price : ₹1/-

Mitomule 2 Injection contains Mitomycin 2mg, a low-dose antineoplastic antibiotic used in oncology for targeted chemotherapy protocols and specialized cancer treatments. It is commonly utilized where controlled dosing is required under strict oncological supervision.

Mitomycin acts by alkylating DNA and inhibiting DNA synthesis, thereby preventing the proliferation of rapidly dividing cancer cells. Its precise dosing strength allows clinicians to tailor therapy based on patient-specific treatment plans.

For distributors and healthcare suppliers, Mitomule 2 Injection is a specialty oncology product, primarily supplied to cancer hospitals, oncology clinics, and tertiary care institutions. Protocol-driven administration ensures consistent and regulated institutional demand.

Adding Mitomule 2 Injection to your oncology and chemotherapy therapy segment creates strong opportunities in hospital supply chains, specialty oncology pharmacies, export markets, and third-party manufacturing. Its essential clinical role, flexible dosing strength, and strong prescriber confidence make it a valuable product within pharmaceutical distribution portfolios.

Read More

About the Product

Mitomule 2 Injection contains Mitomycin 2mg, a low-dose antineoplastic antibiotic used in oncology for targeted chemotherapy protocols and specialized cancer treatments. It is commonly utilized where controlled dosing is required under strict oncological supervision.

Mitomycin acts by alkylating DNA and inhibiting DNA synthesis, thereby preventing the proliferation of rapidly dividing cancer cells. Its precise dosing strength allows clinicians to tailor therapy based on patient-specific treatment plans.

For distributors and healthcare suppliers, Mitomule 2 Injection is a specialty oncology product, primarily supplied to cancer hospitals, oncology clinics, and tertiary care institutions. Protocol-driven administration ensures consistent and regulated institutional demand.

Adding Mitomule 2 Injection to your oncology and chemotherapy therapy segment creates strong opportunities in hospital supply chains, specialty oncology pharmacies, export markets, and third-party manufacturing. Its essential clinical role, flexible dosing strength, and strong prescriber confidence make it a valuable product within pharmaceutical distribution portfolios.

Common side effects may include nausea, vomiting, fatigue, loss of appetite, and bone marrow suppression leading to anemia, leukopenia, or thrombocytopenia. Serious side effects can include kidney toxicity, lung toxicity, severe infections, or bleeding disorders.

Mitomule 2 Injection is indicated for the treatment of various solid tumors including gastric, pancreatic, bladder, and breast cancers, as well as other malignancies as determined by an oncologist. It may be used alone or as part of combination chemotherapy regimens.

Mitomule 2 Injection should be administered only by qualified healthcare professionals experienced in oncology treatments. Regular monitoring of blood counts and renal function is essential during therapy. Patients should inform their doctor about any existing infections, kidney disease, pregnancy, or breastfeeding before receiving this injection.

Store Mitomule 2 Injection in a cool, dry place away from direct light, as per label instructions. Keep out of reach of children. Do not use the injection if the vial is damaged or after the expiry date printed on the packaging.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation